IQVIA Holdings Inc. $IQV Shares Sold by Copperleaf Capital LLC

Copperleaf Capital LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,575 shares of the medical research company’s stock after selling 394 shares during the period. Copperleaf Capital LLC’s holdings in IQVIA were worth $721,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Canada Pension Plan Investment Board raised its holdings in IQVIA by 7.3% during the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after purchasing an additional 312,807 shares in the last quarter. JPMorgan Chase & Co. raised its stake in IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after acquiring an additional 798,534 shares in the last quarter. Nordea Investment Management AB lifted its position in IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares during the last quarter. American Century Companies Inc. boosted its stake in IQVIA by 26.8% in the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock valued at $253,695,000 after acquiring an additional 304,258 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after purchasing an additional 40,699 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Up 0.7%

Shares of NYSE:IQV opened at $217.60 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $228.12. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm’s 50-day simple moving average is $203.84 and its 200-day simple moving average is $179.79. The company has a market cap of $37.06 billion, a price-to-earnings ratio of 29.85, a PEG ratio of 2.43 and a beta of 1.34.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter last year, the firm earned $2.84 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HSBC raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the company an “outperform” rating in a report on Wednesday, October 29th. TD Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating and increased their price target for the stock from $206.00 to $215.00 in a research note on Monday, November 3rd. UBS Group raised their price objective on shares of IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $265.00 target price (up from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $240.61.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.